Skip to main content

Advertisement

SpringerLink
Log in

Novel options for the treatment of castration-resistant prostate cancer

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huggins C (1942) Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 115:1192–1200

    Article  PubMed  CAS  Google Scholar 

  2. Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364:2055–2058

    Article  PubMed  CAS  Google Scholar 

  3. Heidenreich A, Bellmunt J, Bolla M et al (2010) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71

    Article  PubMed  Google Scholar 

  4. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45

    Article  PubMed  CAS  Google Scholar 

  5. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  PubMed  CAS  Google Scholar 

  6. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  7. Locke JA, Guns ES, Lubik AA et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415

    Article  PubMed  CAS  Google Scholar 

  8. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  9. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    Article  PubMed  CAS  Google Scholar 

  10. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  PubMed  CAS  Google Scholar 

  11. Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–556

    Article  PubMed  CAS  Google Scholar 

  12. Culig Z, Hoffmann J, Erdel M et al (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242–251

    Article  PubMed  CAS  Google Scholar 

  13. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665–1671

    Article  PubMed  CAS  Google Scholar 

  14. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168:2439–2443

    Article  PubMed  CAS  Google Scholar 

  15. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  16. Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513

    PubMed  CAS  Google Scholar 

  17. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  18. Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135–2144

    Article  PubMed  CAS  Google Scholar 

  19. Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679

    Article  PubMed  CAS  Google Scholar 

  20. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094

    Article  PubMed  CAS  Google Scholar 

  21. Auchus RJ (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30:101–119 (vii)

    Article  PubMed  CAS  Google Scholar 

  22. Rowlands MG, Barrie SE, Chan F et al (1995) Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17, 20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem 38:4191–4197

    Article  PubMed  CAS  Google Scholar 

  23. Yap TA, Carden CP, Attard G, de Bono JS (2008) Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 8:449–457

    Article  PubMed  CAS  Google Scholar 

  24. Attard G, Reid AH, Olmos D, de Bono JS (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937–4940

    Article  PubMed  CAS  Google Scholar 

  25. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563–4571

    Article  PubMed  CAS  Google Scholar 

  26. Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488

    Article  PubMed  CAS  Google Scholar 

  27. Ryan CJ, Shah S, Efstathiou E et al (2011) Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17:4854–4861

    Article  PubMed  CAS  Google Scholar 

  28. Attard G, Reid AH, A’Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748

    Article  PubMed  CAS  Google Scholar 

  29. Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489–1495

    Article  PubMed  CAS  Google Scholar 

  30. Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496–1501

    Article  PubMed  CAS  Google Scholar 

  31. Scher HI, Heller G, Molina A et al (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. ASCO Meet Abstr 29:LBA4517

    Google Scholar 

  32. Matsunaga N, Kaku T, Ojida A et al (2004) C(17, 20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17, 20)-lyase inhibitors. Bioorg Med Chem 12:4313–4336

    Article  PubMed  CAS  Google Scholar 

  33. Dreicer R, Agus DB, MacVicar GR, MacLean D, ZhangT, Stadier WM (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc, abstract 103

  34. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790

    Article  PubMed  CAS  Google Scholar 

  35. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446

    Article  PubMed  CAS  Google Scholar 

  36. Inoue A, Yanagisawa M, Kimura S et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863–2867

    Article  PubMed  CAS  Google Scholar 

  37. Smollich M, Wulfing P (2007) The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5:239–248

    Article  PubMed  CAS  Google Scholar 

  38. Nelson JB, Udan MS, Guruli G, Pflug BR (2005) Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7:631–637

    Article  PubMed  CAS  Google Scholar 

  39. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M (2001) Expression of endothelin receptor a associated with prostate cancer progression. J Urol 165:1033–1036

    Article  PubMed  CAS  Google Scholar 

  40. Yin JJ, Mohammad KS, Kakonen SM et al (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100:10954–10959

    Article  PubMed  CAS  Google Scholar 

  41. Opgenorth TJ, Adler AL, Calzadilla SV et al (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473–481

    PubMed  CAS  Google Scholar 

  42. Carducci MA, Nelson JB, Bowling MK et al (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20:2171–2180

    Article  PubMed  CAS  Google Scholar 

  43. Samara E, Dutta S, Cao G et al (2001) Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol 41:397–403

    Article  PubMed  CAS  Google Scholar 

  44. Carducci MA, Padley RJ, Breul J et al (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679–689

    Article  PubMed  CAS  Google Scholar 

  45. Nelson JB, Love W, Chin JL et al (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113:2478–2487

    Article  PubMed  CAS  Google Scholar 

  46. Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959–1966

    Article  PubMed  CAS  Google Scholar 

  47. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR (2006) Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 107:530–535

    Article  PubMed  CAS  Google Scholar 

  48. Armstrong AJ, Creel P, Turnbull J et al (2008) A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 14:6270–6276

    Article  PubMed  CAS  Google Scholar 

  49. Morris CD, Rose A, Curwen J et al (2005) Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92:2148–2152

    Article  PubMed  CAS  Google Scholar 

  50. James ND, Caty A, Borre M et al (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55:1112–1123

    Article  PubMed  CAS  Google Scholar 

  51. Nelson JB, Fizazi K, Miller K (2011) Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 29(suppl 7): abstr 117

    Google Scholar 

  52. Nilsson S, Franzen L, Parker C et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587–594

    Article  PubMed  CAS  Google Scholar 

  53. Parker C (2011) Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a Phase III randomized trial (ALSYMPCA). The 2011 European multidisciplinary cancer congress. Stockholm: Eur J Cancer 47(Suppl 2):3

  54. Chi KN, Eisenhauer E, Fazli L et al (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97:1287–1296

    Article  PubMed  CAS  Google Scholar 

  55. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254

    Article  PubMed  CAS  Google Scholar 

  56. Chi KN, Siu LL, Hirte H et al (2008) A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14:833–839

    Article  PubMed  CAS  Google Scholar 

  57. Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730

    Article  PubMed  CAS  Google Scholar 

  58. Pivot X, Koralewski P, Hidalgo JL et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–1552

    Article  PubMed  CAS  Google Scholar 

  59. Shigeta K, Miura Y, Naito Y, Takano T (2011) Cabazitaxel for castration-resistant prostate cancer. Lancet 377:121 (author reply 122–123)

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The following conflict of interest have to be disclosed.

Carsten-H. Ohlmann: Astellas, Bayer Health Care, Sanofi-Aventis, Janssen Cilag, Amgen; Axel S. Merseburger: Ipsen, Astellas, Novartis, Roche, Pfizer, Bayer, Amgen, Medac, TEVA, SEP, Ferring; Henrik Suttmann: medac, Astellas, Sanofi-Aventis, Ferring; David Schilling: Astellas; Lutz Trojan: Astellas, Janssen Cilag, Amgen, Sanofi-Aventis, Bayer Health Care; Carsten Kempkensteffen: Astellas; Stefan Corvin: Astellas; Michael J. Mathers: Astellas; Patrick J. Bastian: Astellas, Dendreon, Janssen Cilag, Amgen, Sanofi-Aventis.

Author information

Authors and Affiliations

  1. Department of Urology, Saarland University, Kirrbergerstr. 1, 66421, Homburg/Saar, Germany

    Carsten-H. Ohlmann

  2. Department of Urology, Hannover Medical School, Hannover, Germany

    Axel S. Merseburger

  3. Urologikum Hamburg, Hamburg, Germany

    Henrik Suttmann

  4. Department of Urology, Eberhard-Karls-University, Tuebingen, Germany

    David Schilling

  5. Department of Urology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

    Lutz Trojan

  6. Department of Urology, Charité, University Medicine Berlin, Berlin, Germany

    Carsten Kempkensteffen

  7. Fachzentrum für Urologie Eggenfelden, Eggenfelden, Germany

    Stefan Corvin

  8. PandaMED Remscheid, Remscheid, Germany

    Michael J. Mathers

  9. Urologische Klinik und Poliklinik, Klinikum der Universität-Campus Großhadern, Ludwig-Maximilians-Universität München, München, Germany

    Patrick J. Bastian

Authors
  1. Carsten-H. Ohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel S. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrik Suttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lutz Trojan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carsten Kempkensteffen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Corvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael J. Mathers
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrick J. Bastian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten-H. Ohlmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohlmann, CH., Merseburger, A.S., Suttmann, H. et al. Novel options for the treatment of castration-resistant prostate cancer. World J Urol 30, 495–503 (2012). https://doi.org/10.1007/s00345-011-0796-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0796-7

Keywords

Search

Navigation